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Abstract
Background: Escalating trends of obesity and associated type 2 diabetes (T2D) has prompted an increase in the use of 
alternative and complementary functional foods. Momordica charantia or bitter melon (BM) that is traditionally used to 
treat diabetes and complications has been demonstrated to alleviate hyperglycemia as well as reduce adiposity in 
rodents. However, its effects on human adipocytes remain unknown. The objective of our study was to investigate the 
effects of BM juice (BMJ) on lipid accumulation and adipocyte differentiation transcription factors in primary human 
differentiating preadipocytes and adipocytes.
Methods: Commercially available cryopreserved primary human preadipocytes were treated with and without BMJ 
during and after differentiation. Cytotoxicity, lipid accumulation, and adipogenic genes mRNA expression was 
measured by commercial enzymatic assay kits and semi-quantitative RT-PCR (RT-PCR).
Results: Preadipocytes treated with varying concentrations of BMJ during differentiation demonstrated significant 
reduction in lipid content with a concomitant reduction in mRNA expression of adipocyte transcription factors such as, 
peroxisome proliferator-associated receptor γ (PPARγ) and sterol regulatory element-binding protein 1c (SREBP-1c) and 
adipocytokine, resistin. Similarly, adipocytes treated with BMJ for 48 h demonstrated reduced lipid content, perilipin 
mRNA expression, and increased lipolysis as measured by the release of glycerol.
Conclusion: Our data suggests that BMJ is a potent inhibitor of lipogenesis and stimulator of lipolysis activity in human 
adipocytes. BMJ may therefore prove to be an effective complementary or alternative therapy to reduce adipogenesis 
in humans.
Background
In the United States, approximately 127 million adults are
overweight (body mass index, BMI > 25 kg/m2) while
more than 60 million are classified as obese (BMI > 30 kg/
m2), and about 9 million as severely obese (BMI > 40 kg/
m2). In the last two decades, the prevalence of overweight
individuals has increased by 40% (from 46.0% to 64.5%)
and the prevalence of obesity has risen by 110% (from
14.5% to 30.5%) [1]. Obesity is also associated with meta-
bolic disorders such as type 2 diabetes (T2D), which is
the second leading cause of preventable death in the
United States [2].
Adipose tissue is a critical endocrine organ that is
innately involved in regulating not only obesity, but also
metabolic processes such as, insulin resistance and type-2
diabetes mellitus (T2DM) [3,4]. Adipogenesis involves
development of preadipocytes to mature adipocytes with
the accumulation of lipid droplets, increase in fat cell size
(hypertrophy), as well as increase in cell number or
hyperplasia and plays an important role in obesity.
Among the various transcription factors that promote
preadipocyte differentiation and influence adipogenesis,
peroxisome proliferator-activated receptor γ (PPARγ) is
considered the "master regulator of adipogenesis" [5,6].
Other adipogenic transcription factors include the
CCAAT/enhancer binding proteins (C/EBPα, C/EBPβ
and C/EBPδ) and sterol regulatory element-binding pro-
tein 1c (SREBP-1c) [7-9]. Similarly, lipolysis or lipid
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mobilization in adipocytes results from breakdown of
adipose triacylglycerols (TAG) into nonesterified fatty
acids (NEAF) and glycerol and involves not only lipases
and TAG hydrolases, but also lipid-droplet coating pro-
teins such as perilipin [10,11]. Besides adipocyte tran-
scription factors, adipocyte-secreted factors
(adipocytokines) also play an important role in primary
human preadipocyte differentiation [12]. Adipocytokine
resistin, a 12-kDa peptide, is increased along with PPARγ
during the differentiation of 3T3-L1 adipocytes [13] and
primary human adipocytes [12]. Overall, an appropriate
balance between adipogenesis and lipolysis is therefore
crucial for the proper functioning of adipose tissue,
which plays an important role in obesity and associated
metabolic functions.
Successful treatment of obesity usually requires multi-
ple interventions such as exercise programs, diet, behav-
ioral modification and pharmacotherapy [14-20].
E s c a l a t i n g  t r e n d s  o f  o be s i t y  h a s  r e s u l t e d  i n  a  r e n ew ed
interest in the use of functional foods including herbs and
alternative medicine [21]. Momordica charantia, com-
monly known as bitter melon (BM), is widely cultivated
in Asia, East-Africa and South America and extensively
used in folk medicines as a remedy for diabetes and its
complications, specifically in India, Southeast Asia,
Africa and South America [22]. Animal studies indicate
that BM juice (BMJ) was also effective in reducing weight
gain, possibly due to reduced adipose hypertrophy, inhi-
bition of lipogenic genes and increased plasma cate-
cholamines [23-26]. However, effects of BMJ on human
adipocyte differentiation are unknown. Therefore, the
goal of our project was to elucidate the effects of BMJ on
lipid accumulation, lipid mobilization, and expression of
adipocyte transcription factors and adipocytokine, in pri-
mary human adipocytes. It was observed that BMJ signif-
icantly reduced lipid accumulation and increased
lipolysis in primary human adipocytes, with a concomi-
tant reduction in PPARγ, SREBP-1c, perilipin, and resis-
tin genes expression. These studies are critical as they lay
the foundation to identify molecular targets and anti-
obesity effects of bitter melon for future clinical trials.
Methods
Preparation of Bitter Melon Juice (BMJ)
Chinese variety of young BM (which had not ripened and
turned yellow/orange) was obtained from local farmer's
market, washed and deseeded. BMJ was extracted
according to the previously published protocol [26,27]. In
brief, young, green BM fruits were deseeded and pulp
was discarded. Juice was prepared in a regular household
juicer and centrifuged at 4,500 rpm at 4°C for 30 min.
About 8,000 g of deseeded BM fruit yielded 3,500 mL of
BMJ. BMJ supernatant was aliquoted and stored at -80°C
until further analysis. Each aliquot was frozen and thawed
only once. The BM variety was verified and identified by
ethnobotanist, Dr. Will McClatchey and voucher speci-
men was deposited at official herbaria, University of
Hawai'i at Manoa, Herbarium (HAW), and labeled as
PratibhaBM0001 and PratibhaBM0002 [26].
Primary Human Adipocyte Cultures
Cryopreserved primary human preadipocytes (catalog #
SP-F-SL, lot # SL0028) were obtained from ZenBio
(Research Triangle Park, NC) and cultured according to
the manufacturer' instructions. The pooled primary
preadipocytes were derived from subcutaneous adipose
tissues of six female donors with an average age of 43
years and average BMI of 27.25 kg/m2. Preadipocytes
were maintained in "Preadipocyte Medium" (cat # PM-1,
ZenBio) and upon confluence, cells were plated in either
96-well, 24-well or 6-well plates at a density of 13,500,
62,500, or 333,333 cells/well, respectively. Two days after
plating, cells were differentiated using "Differentiation
Medium" (catalog # DM-2, ZenBio) and considered as
Day '0'. Media was changed every two days, 2, 4, 6, 8, 10
and 12. Cells were harvested for analysis on day 14, after
which the cells accumulated lipid droplets and were con-
sidered as mature adipocytes. In one set of experiments,
preadipocytes were treated with BMJ during differentia-
tion from day '0' to day 12 and harvested on day 14 for
various analysis. In another set of experiments, when
cells were fully differentiated into adipocytes after 14
days, they were treated with 0.5, 1.0 and 2% BMJ for 24
and 48 h.
Cytotoxicity Measurements
At the end of experimental periods, viability of cells
treated with varying BMJ concentrations (0.5, 1.0, 2.0, 5.0
and 10.0%, v/v) was determined using the ATPlite Lumi-
nescence Detection Assay System (Cat# 6016941, Perkin
Elmer, Boston, MA) according to the manufacturer's pro-
tocol. To determine cell cytotoxicity, media was har-
vested to measure the release of lactate dehydrogenase
(LDH) using CytoTox-ONE Homogeneous Membrane
Integrity Assay (Cat# G7891, Promega) as described pre-
viously [27,28]. Cellular ATP levels are a marker for cell
viability since ATP is present in all metabolically active
cells and the concentration declines rapidly in apoptotic
or necrotic cells.
Oil Red Staining
Oil Red 'O' staining of adipocytes was performed accord-
ing to published protocols [29]. In brief, after washing in
ice-cold PBS cells were fixed overnight in 10% formalin,
washed with water, and stained with 0.3% oil red for 1 h.
After thorough washings with water and evaporation of
excess water, oil red was extracted in isopropyl alcohol
and the absorbance was monitored at 490 nm using Wal-Nerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
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lac Victor2 1420 Multilabel Counter (PerkinElmer Life
Sciences, Boston, MA).
Cellular Triglyceride (TG) Analysis
Preadipocytes were treated either during differentiation,
or after differentiation, with varying concentrations of
BM J as mentioned a bove. Ce lls wer e was hed wit h ice-
cold PBS and lysed with 0.5 N sodium hydroxide (NaOH).
Cellular TG content was measured using the Infinity TG
Liquid Stable Reagent commercial kit (Thermo-DMA, St
Louisville, CO, U.S.A.), and the absorbance was read at
540 nm using Wallac Victor2 1420 Multilabel Counter. TG
values were normalized to mg of protein as determined
by the Bradford method according to the manufacturer's
instructions (Bio-Rad Laboratories, Hercules, CA).
Determination of Lipolysis
L i p o l y s i s  w a s  m e a s u r e d  a s  a  f u n c t i o n  o f  f r e e  g l y c e r o l
released into the medium. In brief, 14 days after differen-
tiation, primary human adipocytes were treated with 0.5,
1 and 2% BMJ for 24 and 48 h. Free glycerol was mea-
sured using the commercial glycerol free reagent and
glycerol standards according to manufacture's protocol
(Sigma, St. Louis, MO).
Semi-Quantitation of mRNA gene expression
To evaluate the mechanism of reduced adipocyte differ-
entiation and lipid accumulation, mRNA gene expression
of peroxisome proliferator-activated receptor gamma
(PPARγ), sterol regulatory element-binding protein -1
(SREBP-1) and resistin genes were determined by semi-
quantitative reverse transcriptase-PCR (RT-PCR) in
preadipocytes treated with varying concentrations of
BMJ during differentiation. To further delineate the
mechanisms underlying lipolysis, perilipin mRNA
expression was determined in adipocytes treated with
BMJ for 48 h. Total RNA was extracted using TRIzol
reagent (TEL-TEST, Inc., Friendswood, TX). Two μg of
RNA was reverse transcribed into complementary DNA
(cDNA) and gene expression levels were quantified by
two-step RT-PCR using the primer pairs and cycling con-
ditions described in Table 1. Various cycling conditions
were initially used to standardize the gene expression
profile in the log phase of amplification. Final cycling
condition was decided based on half of maximum satura-
tion of the amplicons. The PCR amplicon was size-frac-
tionated on a 2% agarose gel and visualized with ethidium
bromide staining. mRNA expressions of various genes
were semi- quantified using the Kodak 1D image analysis
software that captures the intensity of the amplicons and
calculates the pixel counts by normalizing against the
background. The intensities of the amplicon were then
expressed as a ratio of the gene of interest against a
housekeeping gene, GAPDH.
Statistical Analysis
All statistical analysis was performed using GraphPad
Prism, Prism 5 for Windows, version 5.01. Data were
expressed as mean values ± SEM. A one-way or two-way
ANOVA model was used to compare means between the
groups. Each sample was analyzed twice. Post hoc pair-
wise multiple comparisons were evaluated using the
Tukey's Multiple Comparison test or Bonferroni post-
test, after ANOVA. Results were considered significant at
p < 0.05.
Results
BMJ reduces triglyceride (TG) content and increases 
lipolysis in primary human adipocytes
0.5, 1 and 2% BMJ (v/v) was well tolerated and was not
toxic to primary human preadipocytes or adipocytes,
while higher concentrations of BMJ (5 and 10%) was cyto-
toxic as indicated by significantly increased LDH release
and reductions in cellular ATP levels. Preadipocytes
treated with 5% and 10% BMJ during differentiation dem-
onstrated a significant, 31% and 57%, increase in LDH
release when treated, respectively (Figure 1A). Treatment
with 5% BMJ was marginally toxic (19% reduction), while
10% BMJ significantly reduced cell viability by 47% (Fig-
ure 1B) as measured by cellular ATP levels.
Among adipocytes treated with varying BMJ concen-
trations for 24 and 48 h, the trends in cellular ATP levels
and LDH release were similar to the BMJ-treated differ-
entiating adipocytes. Both, 5% and 10% BMJ significantly
increased LDH release by 21% and 51% (Figure 1C). Fig-
ure 1D demonstrates that 5% BMJ non-significantly
reduced cellular ATP by 20%, while 10% BMJ significantly
reduced ATP levels by 32% (p < 0.05) after 48 h. We
therefore used 0.5, 1 and 2% BMJ (v/v) in all our subse-
quent experiments.
Effects of BMJ on cellular differentiation and lipid con-
tents are demonstrated in Figure 2. In contrast to control
adipocytes (Figure 2A), cells treated with 0.5% BMJ (Fig-
ure 2B), 1% BMJ (Figure 2C) and 2% BMJ (Figure 2D) dur-
ing differentiation demonstrate a significant reduction in
lipid content as observed by reduced oil red staining (Fig-
ures 2A to 2D). Figure 2E demonstrates the amount of
total lipid content of cells as measured by organic solvent
extraction of oil 'O' red from cells. A significant (p < 0.05)
dose-dependent reduction in adipocyte differentiation
(25 to 70%) was observed in cells treated with BMJ as
indicated by reduction in oil 'O' red staining (Figure 2E).
Inhibition of differentiation was also accompanied by a
significant reduction (p < 0.05) in cellular TG levels by 40
to 70% in cells treated with BMJ during differentiation, as
compared to control untreated adipocytes (Figure 3A).
Similarly, when adipocytes were treated with BMJ for 24
h and 48 h, cellular TG were significantly reduced (p <
0.05) by 20 to 50% (Figure 3B) with a concomitantNerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
http://www.biomedcentral.com/1472-6882/10/34
Page 4 of 10
increase in lipolysis up to 70% (Figure 3C) (p < 0.05).
Treatment of adipocytes with 2% BMJ induced maximum
TG reduction and lipolysis after 48 h, Figure 3B and 3C,
respectively, but without any significant changes in cellu-
lar morphology.
BMJ reduces mRNA expression of PPARγ, SREBP-1c and 
resistin
Adipocyte transcription factors such as PPARγ and
SREBP-1c, as well as adipocytokine, resistin, play a cru-
cial role in adipocyte differentiation, adipogenesis, and
accumulation of cellular lipid droplets. The fact that BMJ
reduced adipocyte differentiation prompted us to investi-
gate the effects of BMJ on mRNA expression of PPARγ,
SREBP-1c and resistin. Preadipocytes treated with 0.5, 1
or 2% BMJ during differentiation demonstrated a signifi-
cant reduction (p < 0.005) in PPARγ mRNA expression,
50 to 80%, as compared to control untreated adipocytes
(Figure 4). Similarly, a significant (p < 0.05) dose-depen-
dent reduction in SREBP-1c mRNA expression was
observed, further confirming an anti-adipogenic effect of
BMJ (Figure 5). However, reduction in mRNA expression
of resistin gene in preadipocytes treated with 0.5 and
1.0% BMJ during differentiation was not significant as
compared to untreated control cells. In contrast, treat-
ment with 2% BMJ demonstrated a significant reduction
of 45% (p < 0.05) in resistin gene expression (Figure 6).
Overall, maximum inhibition of adipocyte differentiation
and transcription factors was observed with 2% BMJ.
BMJ inhibits perilipin mRNA expression
Formation of lipid droplets in adipocytes as well as lipoly-
sis is regulated by a membrane protein surrounding the
lipid droplets, perilipin, which is also a downstream tar-
get of PPARγ in adipocytes. BMJ-associated reduction in
cellular TG (Figure 3B) and increased lipolysis (Figure
3C) in adipocytes, was accompanied by a significant
reduction (p < 0.05) of perilipin gene mRNA expression
in adipocytes treated with BMJ for up to 48 h (Figure 7).
There was no significant change in morphological
appearance of the cells or cell death, but reduction in lipid
size droplets.
Discussion
Bitter melon is used to treat diabetes and its complica-
tions in traditional Chinese and Ayurvedic medicine. We
and others have demonstrated that besides improving
glucose and lipid metabolism [26,30-32], BMJ is also
effective in improving hyperlipidemia in diabetic and
obese rodents as well as reduces body weights in mice fed
high-fat diet [24,25,33]. However, the effects of bitter
melon on human adipocytes have not been investigated.
Transition of undifferentiated fibroblastic preadipocytes
into mature adipocytes involves differential regulation of
adipogenic genes as well as lipid accumulation. Increase
in fat mass is a result of not only increase in adipocyte
number due to proliferation, but also induction of differ-
entiation that stimulates mitotic clonal expansion and
Table 1: Oligonucleotide primer sequences used in RT-PCR
Target Gene Primer sequence Cycling condition Size (bp)
PPAR γ2 Forward 5'-GCATGGTGCCTTCGCTGATGC-3'
Reverse 5'-AGGCCTGTTGTAGAGCTGGGT-3'
95°C/5 min
95°C/1 min,55°C/1 min
72°C/1 min,72°C/7 min
4°C hold, 33 cycles
340
SREBP-1c Forward 5'-TTGCGCAAGGCCATCGACTACATT-3'
Reverse 5'-ACAAGGGGCTGCTCTGGAAAGGTG-3'
94°C/5 min
94°C/1 min,55°C/1 min
72°C/1 min,72°C/7 min
4°C hold, 26 cycles
238
Perilipin Forward 5'-TGGAGACTGAGGAGAAGAAG-3'
Reverse 5'-ATGTGAGAGGGGAGATGG-3'
94°C/1.5 min
94°C/45 sec,52°C/1.5 min
72°C/1 min,72°C/7 min
4°C hold, 23 cycles
120
Resistin Forward 5'-TGGTGGTGGTGGCTGTCCTGG-3'
Reverse 5'-GAGTGAGATGTGGTCTGGGCG-3'
95°C/2 min
95°C/45 sec,55°C/1.5 min
72°C/45 sec,72°C/7 min
4°C hold, 39 cycles
145
GAPDH Forward 5'-AGTCAGCCGCATCTTCTTTTG-3'
Reverse 5'-CTCCTGGAAGGGAGATGG-3'
Condition adjusted as per the target gene 298Nerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
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irreversible commitment to differentiation [34]. There-
fore, reduction in fat mass during weight loss may involve
inhibition of adipogenic process and lipid accumulation
due to dedifferentiation, lipid mobilization (lipolysis)
and/or programmed cell death (apoptosis). Higher con-
centrations of BMJ at 5% and 10% demonstrate significant
reduction in cell viability as indicated by reduced cellular
ATP levels and increased LDH release. It is therefore pos-
sible that higher concentration of BMJ induces apoptosis
in maturing preadipocytes and adipocytes, which
requires further investigation.
During normal adipogenesis, growth arrest after con-
fluency is followed by mitotic expansion and adipogenic
signals to induce differentiation and lipid accumulation
[35]. Mitotic clonal growth is accomplished by increased
expression of CCAAT/enhancer binding protein beta (C/
EBPβ) which further stimulates the expression of two
transcription factors, C/EBPα and PPARγ involved in adi-
pogenesis and lipogenesis [36]. Our data indicates that
lower concentrations of BMJ (0.5% to 2%) has no effect on
growth arrest or cell death, but may possibly promote
dedifferentiation of maturing preadipocytes via reduction
in PPARγ mRNA gene expression and reduction in lipo-
gensis. Although we did not measure C/EBPα, it is possi-
ble that effects of BMJ are mediated upstream via C/
EBPβ. To our knowledge, this is a first study to elucidate
the effects of BMJ on primary human adipocyte differen-
tiation and analyze the adipogenic gene expressions.
PPARγ, a nuclear hormone receptor, plays a critical role
in peripheral glucose homeostasis and energy metabo-
lism and has been implicated in modulating adipogenesis
and insulin sensitivity in vivo. Anti-diabetic agents such
as rosiglitazone are PPARγ agonist and improve glucose
metabolism by increasing adipogenesis thereby leading to
secondary weight gain [37]. Recent studies indicate that
partial PPARγ antagonism by various plant extracts may
be beneficial in improving insulin sensitivity and may also
inhibit adipocyte differentiation and lipid accumulation
[34,38,39]. In the present studies, BMJ significantly inhib-
Figure 1 Cytotoxicity of bitter melon juice in human predaipo-
cytes and adipocytes. Higher concentrations of BMJ, 5% and 10%, 
significantly increased LDH release and reduced total ATP levels in 
both, differentiating preadipocytes and adipocytes. Lower concentra-
tions of BMJ, 0.5% to 2%, did not affect cell viability or cell proliferation 
in either differentiating preadipocytes or adipocytes. (A) LDH release 
and (B) cellular ATP levels in preadipocytes treated with BMJ during dif-
ferentiation. Similarly, LDH release and cellular ATP levels in adipocytes 
treated with BMJ for 48 h, is depicted in Figures 1D and 1E, respectively. 
Values represent the mean ± SE (n = 6) of three independent experi-
ments conducted in duplicate. a, b, c, dMean values with common letters 
do not differ (p < 0.05).
Figure 2 Effect of bitter melon juice on cellular lipid droplets. To-
tal cellular lipid contents were significantly reduced in preadipocytes 
undergoing differentiation when treated with varying concentrations 
of BMJ (Figures 2A - 2C). Light microscopic pictures of oil red 'O' stain-
ing in untreated control adipocytes (A), and preadipocytes treated 
with - 0.5% BMJ (B), 1% BMJ (C) or 2% BMJ (D), during differentiation 
(40× magnification). Figure 1E depicts degree of preadipocyte differ-
entiation during treatment as measured by total amount of extracted 
oil "O" red. Values represent the mean ± SE (n = 6) of three indepen-
dent experiments conducted in duplicate. a, b, c, dMean values with 
common letters do not differ (p < 0.05).Nerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
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ited adipogenesis in differentiating preadipocytes with a
concomitant reduction in PPARγ gene expression.
We further observed that SREBP-1c, another regulator
of lipid homeostasis and adipogenesis [40] was signifi-
cantly reduced by BMJ in primary human adipocytes
with a simultaneous reduction in cellular lipid content
indicated by reduced oil 'O' red staining. Studies by
Huang et al. indicated that BM powder, prepared from
whole fruit, inhibited adipocyte hypertrophy in diet-
induced obese (DIO) rats possibly due to reduction in the
expression of lipogenic genes including fatty acid syn-
thase (FAS), acetyl CoA carboxylase (ACC 1), lipoprotein
lipase (LPL) and adipocyte fatty acid-binding protein
(aP2) in epididymal fat, which are down-stream targets of
SREBP-1c [25]. However, Huang et al. did not observe
any effects on either PPARγ or SREBP-1c mRNA expres-
sion in the adipose tissue of rats fed HFD and BM, but
suggested possible effects of BM on either the protein
levels or post-transcriptional modifications of these
genes [25].
Adipocytokines such as leptin and adiponectin,
involved in food intake, energy metabolism and weight
gain have been demonstrated to be regulated by BMJ in
cell culture and rodent studies [41,42]. It has been
recently demonstrated that adipocytokine, resistin, is
involved in human adipocyte differentiation [12]. In our
study, BMJ significantly reduced mRNA expression of
resistin in primary human adipocytes treated during dif-
ferentiation. Similarly, Shih et al. [42] also demonstrated a
significant reduction in adipose resistin expression in
mice fed HFD with BMJ. Among obese individuals, the
increased plasma resistin has been demonstrated to posi-
tively correlate with changes in BMI and visceral fat as
well as mRNA expression in abdominal fat [43,44]. The
Figure 3 Effect of bitter melon juice on cellular triglyceride mass. 
Cellular triglyceride levels were reduced in (A) differentiating preadipo-
cytes treated with varying concentrations of BMJ during differentiation 
and (B) adipocytes treated with varying concentrations of BMJ for 24 
and 48 h. Figure 3C depicts the increased release of glycerol into the 
media, when adipocytes were treated with varying concentration of 
BMJ (0.5% to 2%, v/v) for 24 and 48 h. Values represent the mean ± SE 
(n = 6) of three independent experiments conducted in duplicate. a, b, 
c, dMean values with common letters do not differ (p < 0.05).
Figure 4 Effect of bitter melon juice on PPARγ mRNA expression. 
Differentiating preadipocytes treated with varying concentrations of 
BMJ demonstrate a significant reduction in PPARγ mRNA gene expres-
sion. Bar graphs depict the densitometry scans of PPARγ amplicons 
(348-bp) and are expressed as a ratio to GAPDH amplicon (298-bp) in-
tensity. Data are expressed as a percentage of the control (set as 100%) 
and the values represent the mean ± SE (n = 6) of three independent 
experiments analyzed in duplicate. a, b, cMean values with common let-
ters do not differ (p < 0.05).Nerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
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f a ct  t h a t  p las m a  r e s i s t i n  l ev e l s  a r e  r ed u c ed  i n  s u b j ects
with moderate weight loss [45] and our data indicating
reduced resistin expression in primary human adipo-
cytes, supports the hypothesis that BMJ possess an anti-
adipogeneic potential in humans.
Additional mechanisms for reduced adiposity in BMJ-
fed rodents may include increased levels of plasma cate-
cholamines that are known to promote lipolysis in adi-
pose tissue [24]. Perilipins are the most abundant lipid
droplet-specific proteins that influence adipocyte TG
storage and accumulation by regulating lipolysis [46].
They are synthesized on free ribosomes rather than on
endoplasmic reticulum-bound ribosomes and require
post-translational assembly onto lipid droplets [46]. Per-
ilipins also regulate lipolysis by modulating the access of
hormone sensitive lipases (HSL) to the surface of lipid
droplet [47]. Although post-transcriptional phosphoryla-
tion of perilipin via G-protein coupled receptor-activated
protein kinase A (PKA) is associated with increased lipol-
ysis in human adipocytes [48], studies with TNFα indi-
cate that adipocyte lipolysis was also associated with
inhibition of perilipin mRNA expression [49]. Similarly,
our data also indicate that lipolytic activity of BMJ is pos-
sibly associated with significant inhibition of perilipin
mRNA expression. Since perilipin is a down-stream tar-
get of PPARγ, it is highly possible that BMJ may interfere
with ligand-binding domain of PPARγ or may inhibit
endogenous PPARγ ligands and block PPARγ target
genes. Alternatively, we cannot overrule the possibility
that BMJ can directly phosphorylate perilipin proteins by
activation of G-protein coupled receptors.
The range of BMJ concentrations used in the current
study is comparable to those used in earlier studies [26].
However, the exact effective and safe dose of BMJ for
Figure 5 Effect of bitter melon juice on SREBP-1c mRNA expres-
sion. Differentiating preadipocytes treated with varying concentra-
tions of BMJ (0.5% to 2%, v/v) demonstrate a significant reduction in 
SREBP-1c mRNA gene expression. Bar graphs depict the densitometry 
scans of SREBP gene amplicons (238-bp) and are expressed as a ratio 
to GAPDH amplicon (298-bp) intensity. Data are expressed as a per-
centage of the control (set as 100%) and the values represent the 
mean ± SE (n = 6) of three independent experiments analyzed in du-
plicate. a, b, cMean values with common letters do not differ (p < 0.05).
Figure 6 Effect of bitter melon juice on resistin mRNA expression. 
Differentiating preadipocytes treated with varying concentrations of 
BMJ (0.5% to 2%, v/v) demonstrate a significant reduction in resistin 
mRNA gene expression. Bar graphs depict the densitometry scans of 
resistin gene amplicons (145-bp) and are expressed as a ratio to GAP-
DH amplicons (298-bp) intensity. Data are expressed as a percentage 
of the control (set as 100%) and the values represent the mean ± SE (n 
= 6) of three independent experiments analyzed in duplicate. a, b, 
cMean values with common letters do not differ (p < 0.05).Nerurkar et al. BMC Complementary and Alternative Medicine 2010, 10:34
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human consumption is unknown and requires further
clinical evaluation. BMJ contains many active chemicals
including charantin (a steroid glycoside), polypeptide "p"
or plant insulin (a 166 residue insulin mimetic peptide)
[50], glycosides such as mormordin, vitamin C, carote-
noids, flavanoids and polyphenols [51,52]. Our unpub-
lished observations and those by Islam et. al. [53] indicate
that BMJ contains various polyphenols including querce-
tin and gallic acids. Quercetin has been demonstrated to
inhibit adipogenesis and induce apoptosis in 3T3-L1
mouse adipocytes [54,55], while gallic acid is known to
increase the number of early and late apoptotic 3T3-L1
cells in culture via loss of mitochondrial membrane
potential [56]. We therefore speculate that insulin-
mimetic peptides as well as polyphenols such as querce-
tin and gallic acid may in part be responsible for anti-adi-
pogenic properties of BMJ. Recent studies indicate that
cucurbutanoid compounds are the active principals of
BMJ which possess hypoglycemic properties [57], but the
exact active ingredients possessing hypolipidemic prop-
erties are unknown.
Overall our studies demonstrate that BMJ inhibits pri-
mary human adipocyte differentiation by reducing
PPARγ, SREBP and perilipin mRNA gene expression and
by increasing lipolysis. In animal studies, although BMJ
reduced adiposity, Shih et al. demonstrated that adipose
PPARγ mRNA expression was significantly increased in
DIO mice fed BMJ extracts and HFD, as compared to
both, HFD-fed and control mice [42], while Huang et al.
did not observe any effects on adipose lipolysis in rats fed
HFD with BM [25]. These differences are possibly due to
differences in the model system (primary human adipo-
cytes vs. rodents), BM preparations and/or experimental
conditions.
A few clinical studies have investigated the anti-dia-
betic effects of BMJ in humans [58-62], however, long-
term studies testing the effects of BMJ on glucose and
lipid metabolism, body weight as well as identifying the
pharmacokinetics and effective dose of BMJ is warranted,
before it can be recommended as an effective alternative
and/or complementary therapy. Regardless of its thera-
peutic effects, use of BMJ with other hypoglycemic or
hypolipidemic agents must be performed with caution
and under medical supervision due to its hypoglycemic
properties [63,64] and excessive consumption must be
avoided due to possible side effects such as diarrhea [61].
Conclusions
Bitter melon was effective in reducing lipid accumulation
in primary human adipocytes by regulating adipogenic
transcription factors and adipocytokine gene expression.
Future studies are warranted to test the effects of BM
consumption on weight loss and body fat accumulation in
humans.
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